© 2004, the authors Evidenced-based Complementary and Alternative Medicine, Vol. 1, Issue 2 © Oxford University Press 2004; all rights reserved. The online version of this article has been published under an open access model. Users are entitled to use, reproduce, disseminate, or display the open access version of this article provided that: the original authorship is properly and fully attributed; the Journal and Oxford University Press are attributed as the original place of publication with the correct citation details given; if an article is subsequently reproduced or disseminated not in its entirety but only in part or as a derivative work this must be clearly indicated.
Commentary |
Commentary on Traditional and Modern Biomedical Prospecting: Part II—The Benefits by Werner E.G. Müller, Heinz C. Schröder, Matthias Wiens, Sanja Perovi
-Ottstadt, Renato Batel and Isabel M. Müller
Anti-protozoa and antiviral activities of non-cytotoxic truncated and variant analogues of mussel defensin by P. Roch, A. Beschin and E. Bernard
| The first 150 words of the full text of this article appear below. |
 |
Marine Natural Products and their Applications |
|---|
Drug Candidates and their Potential as Anti-Infective Agents
This commentary continues to focus on the two papers cited in the editorial and naturally also alludes to other papers as we continue to emphasize the value of molecules derived from terrestrial and marine species for CAM (1–8). In recent years, marine natural product bioprospecting has yielded a considerable number of drug candidates (9). Most of these molecules are still in preclinical or early clinical development but some are already in the market, such as cytarabine, and it is predicted that some, such as ET743 (Yondelis), will be approved in near future. The ecology of marine natural products reveals that many of these compounds are chemical weapons and have evolved into highly potent inhibitors of physiological processes in the prey, predators or competitors of the marine organisms that utilize them for survival. Certain natural products isolated from marine invertebrates have been shown to be,
Enhancing Marine Natural Product Structural Diversity and Bioactivity through Semisynthesis and Biocatalysis
|
Novel Antitumor Agents from Invertebrates and a Cartilaginous Fish—the Shark |
|---|
Coral Reefs, Forests and Thermal Vents: The Worldwide Exploration of Nature for Novel Antitumor Agents
Squalamine and cisplatin block angiogenesis and the growth of human ovarian cancer cells with or without HER-2 gene overexpression
|
Anti-HIV Activity of Natural Products from Marine Organisms |
|---|
|
Perspectives on Novel Discoveries as Contributors to Complementary and Alternative Therapies |
|---|
Professor and Editor-in-Chief, Laboratory of Comparative Neuroimmunology, Department of Neurobiology, David Geffen School of Medicine, University of California, Los Angeles, California 90095–1763, USA. Tel: 310-825-9567; Fax: 310-825-2224. E-mail: ecam@mednet.ucla.edu
CiteULike 
Connotea 
Del.icio.us What's this?
Related articles in eCAM:
- Traditional and Modern Biomedical Prospecting: Part II—the Benefits: Approaches for a Sustainable Exploitation of Biodiversity (Secondary Metabolites and Biomaterials from Sponges)
- Werner E.G. Müller, Heinz C. Schröder, Matthias Wiens, Sanja Perovic-Ottstadt, Renato Batel, and Isabel M. Müller
eCAM 2004 1: 133-144.[Abstract] [FREE Full Text]
This article has been cited by other articles:
|
|
 |
|
  A. Premgamone, P. Sriboonlue, S. Maskasem, W. Ditsataporncharoen, and B. Jindawong Orthosiphon Versus Placebo in Nephrolithiasis with Multiple Chronic Complaints: A Randomized Control Trial Evid. Based Complement. Altern. Med., December 1, 2009; 6(4): 495 - 501. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Nigam, A. Bexfield, S. Thomas, and N. A. Ratcliffe Maggot Therapy: The Science and Implication for CAM Part II--Maggots Combat Infection Evid. Based Complement. Altern. Med., September 1, 2006; 3(3): 303 - 308. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. L. Cooper eCAM benefits from diversity that derives from CAM Evid. Based Complement. Altern. Med., September 1, 2005; 2(3): 263 - 265. [Full Text] [PDF]
|
|